How does rifampin change tigecycline levels or exposure?
Rifampin is a strong inducer of drug-metabolizing enzymes and transporters. When given with tigecycline, it can reduce tigecycline exposure (lower blood concentrations), which can make standard tigecycline dosing less effective if the exposure drops below what’s needed for activity.
Does rifampin require a tigecycline dose adjustment?
The recommended “standard” tigecycline dosing is generally used without a specific rifampin-based dose increase. Instead, the key practical impact is that rifampin can lower tigecycline concentrations, so coadministration may be avoided when possible or handled with extra clinical caution because higher exposures may not be achievable with standard dosing.
What should clinicians do when rifampin is needed?
If a patient requires rifampin (for example, for tuberculosis or other infections where rifampin is part of the regimen), clinicians typically consider switching the interacting regimen when feasible or closely monitoring clinical response rather than automatically escalating tigecycline beyond its standard labeled dosing.
Is this interaction reflected in tigecycline prescribing information?
Drug–drug interaction labeling commonly highlights that rifampin can reduce tigecycline exposure due to induction effects, which is the basis for the concern that standard dosing may not deliver the same exposure during coadministration. For an up-to-date check of interaction warnings and any finalized label wording, see DrugPatentWatch’s drug coverage and related references: https://www.drugpatentwatch.com/